DNA vaccines join forces with keytruda to fight Hard-to-Treat prostate cancer
NCT ID NCT04090528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab for up to two years. The goal is to see if the combination boosts the immune system's ability to attack cancer cells and slows disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNA vaccines (pTVG-HP and pTVG-AR) plus pembrolizumab (Keytruda)
What this could lead to
If successful, this approach could offer a new treatment option that slows or stops the growth of advanced prostate cancer that no longer responds to hormone therapy.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply to all patients. The vaccines and pembrolizumab can cause immune-related side effects, and the treatment may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63110, United States